{
  "meta": {
    "data_length": 1,
    "message": "Indication id ind:hc:tasigna:4 retrieved successfully",
    "request_url": "http://api.moalmanac.org/indications?indication_id=ind%3Ahc%3Atasigna%3A4",
    "status": "success",
    "status_code": 200,
    "timestamp_elapsed": 0.001642,
    "timestamp_received": "2026-09-25T00:11:54.491430+00:00Z",
    "timestamp_returned": "2026-09-25T00:11:54.493072+00:00Z",
    "trace_id": "4325e59b-d6a8-4a80-a9eb-75c9cec8048e"
  },
  "service": {
    "github": "https://github.com/vanallenlab/moalmanac-db",
    "name": "Molecular Oncology Almanac",
    "license": "GPL-2.0",
    "release": "draft",
    "url": "https://dev.moalmanac.org",
    "last_updated": "2026-08-02"
  },
  "data": [
    {
      "id": "ind:hc:tasigna:4",
      "type": "Indication",
      "description": "TASIGNA (nilotinib) is indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP).",
      "contributions": [],
      "reportedIn": [
        {
          "id": "doc:hc:tasigna",
          "type": "Document",
          "documentType": "Regulatory approval",
          "name": "Tasigna (nilotinib) [product monograph]. HC.",
          "title": null,
          "aliases": [],
          "description": "Novartis Pharmaceuticals Canada Inc. Tasigna (nilotinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076372.PDF. Revised July 2024. Accessed June 2025.",
          "urls": [
            "https://pdf.hres.ca/dpd_pm/00076372.PDF",
            "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80138"
          ],
          "doi": null,
          "pmid": null,
          "extensions": [
            {
              "name": "agent",
              "value": {
                "id": "agent:org:hc",
                "type": "Agent",
                "agentType": "organization",
                "name": "Health Canada",
                "description": "Regulatory agency that approves drugs for sale and use in Canada."
              },
              "description": "The organization that published this document."
            },
            {
              "name": "company",
              "value": "Novartis Pharmaceuticals Canada Inc.",
              "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_brand",
              "value": "Tasigna",
              "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_generic",
              "value": "nilotinib",
              "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "first_publication_date",
              "value": "2008-09-30",
              "description": "The publication date for the initial version of this document."
            },
            {
              "name": "identification_number",
              "value": null,
              "description": "Identification number used by the publishing organization."
            },
            {
              "name": "publication_date",
              "value": "2024-07-17",
              "description": "The publication date for the document."
            },
            {
              "name": "status",
              "value": "Active",
              "description": "Whether this document is Active or Deprecated within moalmanac-db."
            }
          ]
        }
      ],
      "extensions": [
        {
          "name": "status",
          "value": "Approved",
          "description": "Current approval status."
        }
      ]
    }
  ]
}